USP 797 Clean Room Guidelines & Standards

What is USP 797?

USP 797 is a far-reaching regulation that applies to health care institutions, pharmacies, physicians practice facilities, and other facilities in which compound sterile preparations are prepared, stored, and dispensed. The purpose of the regulation is to prevent infections in patients using pharmaceutical products, as well as to protect pharmacy staff members that are ordinarily exposed to pharmaceutical products. Below is a summary of the USP 797 regulation.

For more information, visit the USP 797 website. You can also download the entire ASHP Discussion Guide for Compounding Sterile Preparations document here.

Summary of USP 797: Pharmaceutical Labs & Sterile Compounding

Source of base information: Pharmacopeial Form - Volume 29 (4) July - August 2003
Effective Date: January 1, 2004
FDA enforceable: yes

usp 797 clean roomScope - "The content of this chapter applies to health care institutions, pharmacies, physicians practice facilities and other facilities in which compounds sterile preparations are prepared, stored and dispensed."

Facilities Impacted by USP 797

  1. Facilities in which sterile products are prepared according to the manufacturer's labeling and where manipulations are performed during the compounding of sterile products which increase the potential for microbial contamination of the end product.
  2. Facilities where products are compounded using devices or ingredients which are not sterile to prepare products which must be sterilized prior to use.
  3. Products may be biologics, diagnostics, drugs, nutrients, or radiopharmaceuticals which include, but are not limited to, baths and soaks for live organs and tissues, implants, inhalations, injections, irrigations, metered sprays, ophthalmic and otic preparations.

Microbial Contamination Risk Levels

Low Risk Conditions: Compounding with aseptic manipulations entirely with ISO Class 5 or better air quality using only sterile ingredients, products, compounds and devices.

Examples:

  • Using sterile needles and syringes to transfer sterile drugs from the manufacturer's original packaging (vials, ampoules).
  • Manually measuring and mixing no more than three sterile products to compound drug admixtures and nutritional solutions.

Medium Risk Conditions: Multiple individual or small doses of sterile products are compounded or pooled to prepare a compound sterile product that will be administered either to multiple patients or to one patient on multiple occasions. The compounding process includes complex aseptic manipulations other than the single volume transfer. The compounding process requires and unusually long duration, such as that required to complete dissolution or homogenous mixing. The compounded sterile products do not contain broad spectrum bacteriostatic substances and they are administered over several days. For a medium risk preparation in the absence of passing a sterility test, the storage period cannot exceed the following time periods: 30 hours at room temperature, 7 days at cold temperature, and 25 days in a solid frozen state at -20 C or colder

Examples:

  • TPN fluids compounded using manual or automated devices requiring multiples injections, detachments, and attachments of the nutrient source products to the device or machine to deliver all nutritional components to the final sterile container.
  • Filling of reservoirs of injection and infusion devices with multiple sterile drug products and evacuations of air from these reservoirs before the filled device is dispensed.
  • Filling of reservoirs of injection and infusion devices with volumes or sterile drug solutions that will be administered over several days at ambient temperatures between 25 and 40 degrees.
  • Transfer of multiple ampoules or vials into a single final sterile container or products.

High Risk Conditions: Non-sterile ingredients including manufactured products for routed of administration other than those listed under c in the in introduction are incorporated or a non-sterile device is employed before terminal sterilization. Sterile ingredients, components, devices and mixtures are exposed to air quality inferior to ISO Class 5. This includes storage in environments inferior to ISA Class 5 of opened or partially used packages or manufactured sterile products that lack antimicrobial preservatives. Non-sterile products are exposed to air quality inferior to ISA Class 5 for at least 6 hours before sterilization. For high risk preparations in the absence of passing a sterility test the storage periods cannot exceed the following; 24 hours at controlled room conditions, 3 days at cold temperatures and 45 days for solid frozen state at -20 C or colder.

Examples:

  • Dissolving non-sterile bulk drug and nutrient powders to make solution, which will be terminally sterilized.
  • Sterile ingredients, components, devices, and mixtures are exposed to air quality inferior to ISO Class 5. This includes storage in environment inferior to ISO Class 5 of opened or partially used packaged of manufactured sterile products that lack antimicrobial preservatives.
  • Measuring and mixing sterile ingredients in non-sterile devices before sterilization is preformed.

Personnel Training and Evaluation in Aseptic Manipulations Skills

usp 797 clean room sterile compoundingPersonnel who prepare compounded sterile products must be provided with appropriate training from expert personnel, audio-video instructional sources, or professional sour-ces before beginning to prepare products. Personnel shall perform didactic review, writ-ten testing, media fill testing or aseptic manipulative shills initially and at least annually for low and medium risk levels and semi annually for high risk level compounding. Media fill challenge testing will be used to access the quality of aseptic skills.

Clean Rooms

Low and Medium Risk:

  • Must have an ante area but need not be separated with a physical wall.
  • Air classification or quality must meet ISO class 8 standards Class 100,000 (ISO 8).
  • Positive pressure to adjacent areas per ISO 14644-4.
  • Physical characteristics of construction: Walls, floors, fixtures and ceilings should be smooth, impervious and free of cracks, crevices and non-shedding. Surfaces should be resistant to damage from sanitizing agents. Junctures of ceilings to walls should be coved and caulked. If ceilings consist of inlaid panels, the panels should be impregnated with a polymer to render them impervious and hydrophobic and they should be caulked around each perimeter to seal them to the support frame. Walls may be panels locked together and sealed or epoxy coated gypsum board. Floors should be overlaid with side sheet vinyl flooring with heat-sealed seams and coving at the sidewall. The buffer or ante area should contain no sinks or floor drains.
  • Gowning: Before entering the ante or buffer area personnel should remove outer lab coats, make-up, and jewelry, and thoroughly scrub hands and arms to the elbows. After drying hands and arms they should don clean non-shedding uniforms consisting of: Hair covers, Shoe covers, Coveralls or knee length coats (coats to fit snuggly at the wrists and be zipped or snapped in the front), Appropriate gloves, Facemasks should be put on after entering the cleanroom.
  • Leaving and Reentry: Upon leaving the clean room the coveralls or coats should be carefully removed and hung outside the entry in the buffer area. Coveralls and coats can be used for one shift. All other coverings are to be discarded and new ones donned prior to reentry. Reentry follows original procedure.

High Risk:

  • All of the low to medium risk procedures and facilities excepts the ante area must be a separate room.

Barrier Isolator (MIC)

A well-designed barrier isolator is an alternative to an ISO class 5 (class 100) LAFW device in an ISO class 8 clean room. The barrier isolator should be supported by adequate procedures for operation, maintenance, monitoring, and control. It is not necessary to locate the barrier isolator in an ISO class 8 area. Gowning: Hair covers, Shoe covers, Lab Coats, Facemasks (for covering facial hair).

Quality Assurance Program

Must have formal audit program which:

  • Is formalized in writing
  • Considers all aspects of preparation and dispensing
  • Describes specific monitoring and evaluation activities
  • Has specifications on how results are to be reported and evaluated
  • Identifies appropriate follow-up mechanisms when action limits or thresholds are exceeded.
  • Has delineation of the individual responsible for each aspect of the QA program.

USP 797 Guidelines - Minimum Requirements for Validation

Low to Medium Risk:

  • Personnel validation - Three consecutive media fill runs without contamination.
  • Revalidation - One media fill run quarterly without contamination
  • Failure of revalidation - Three consecutive media sill runs without contamination

High Risk:

  • Personnel validation - Three consecutive media fills run without contamination
  • Revalidation -One media fill run quarterly without contamination
  • Failure of revalidation - Three consecutive media sill runs without contamination
  • Process validation - Three consecutive media sill runs without contamination
  • Revalidation - One media fill run annually without contamination
  • Failure of revalidation - Three consecutive media sill runs without contamination

Cleaning and sanitizing the workspaces:

  • Written procedures
  • Perform at the beginning of each shift

Environmental Monitoring Required

  • Verification of sterile compounding equipment
  • Written plan and schedule for monitoring airborne organisms
  • Verification of particulate
  • Verification of viable microorganisms

Verification of automated compound devices for nutrition compounding Required

  • Sterility Testing
  • All high risk compounded sterile products administered by injection into vascular an central nervous systems that are prepared in groups of 25 identical or single dose packaged or in multi-dose vials for administration in multiple patients.